Nature Reviews Drug Discovery

Embracing the avoid-ome

Asher Mullard Nov 01, 2025 pp. 820-821 10.1038/d41573-025-00169-w

FDA new drug approvals in Q3 2025

Paul Verdin Nov 01, 2025 pp. 817-817 10.1038/d41573-025-00170-3

Innovation in medicines for global health: a 20-year landscape analysis

Paul Ashigbie, Rajiv Shah, Thierry Diagana et al. Nov 01, 2025 pp. 818-819 10.1038/d41573-025-00164-1

Cancer cachexia contender enters first pivotal trial

Asher Mullard Nov 01, 2025 pp. 811-814 10.1038/d41573-025-00168-x

Roche buys MASH contender for up to US$3.5 billion

Asher Mullard Nov 01, 2025 pp. 816-816 10.1038/d41573-025-00167-y

FDA approves BTK inhibitor for chronic hives

Asher Mullard Nov 01, 2025 pp. 815-815 10.1038/d41573-025-00165-0

Genmab nabs EGFR × LGR5 bispecific in US$8 billion Merus acquisition

Asher Mullard Nov 01, 2025 pp. 815-815 10.1038/d41573-025-00166-z

Designer peptide retunes channel function

Katie Kingwell Nov 01, 2025 pp. 825-825 10.1038/d41573-025-00163-2

Macrocyclic peptides challenge cell cycle defects

M. Teresa Villanueva Nov 01, 2025 pp. 826-826 10.1038/d41573-025-00162-3

Rebalancing cardiolipin biosynthesis to treat cardiomyopathy

Alex Eccleston Nov 01, 2025 pp. 826-826 10.1038/d41573-025-00161-4

Targeting GPR31 to treat MASH

Sarah Crunkhorn Nov 01, 2025 pp. 827-827 10.1038/d41573-025-00158-z

Blocking SLC38A2 lowers blood pressure

Sarah Crunkhorn Nov 01, 2025 pp. 827-827 10.1038/d41573-025-00157-0

A degrader of oncoprotein SKP2

Sarah Crunkhorn Nov 01, 2025 pp. 827-827 10.1038/d41573-025-00159-y

Designing new antibiotics

Sarah Crunkhorn Nov 01, 2025 pp. 827-827 10.1038/d41573-025-00160-5

Overcoming roadblocks to anti-inflammatory NLRP3 inhibitors

Sarah Crunkhorn Nov 01, 2025 pp. 824-824 10.1038/d41573-025-00156-1

The non-small-cell lung cancer drug market

Charlotte B. Jago, Rachel M. Webster Nov 01, 2025 pp. 822-823 10.1038/d41573-025-00123-w

RNA chemistry and therapeutics

Siyu Wang, Drew Weissman, Yizhou Dong Nov 01, 2025 pp. 828-851 10.1038/s41573-025-01237-x

The changing landscape of medicinal chemistry optimization

Anita Rácz, Levente M. Mihalovits, Maximilian Beckers et al. Nov 01, 2025 pp. 870-887 10.1038/s41573-025-01225-1

Targeting the Hippo pathway in cancer

Kieran F. Harvey, Tracy T. Tang Nov 01, 2025 pp. 852-869 10.1038/s41573-025-01234-0

Accelerating precision oncology by converging pragmatic trials and real-world evidence

Kjetil Taskén, Piers Mahon Nov 01, 2025 pp. 809-810 10.1038/d41573-025-00047-5